2187368-16-5
Chemical Structure
Lacutamab
Synonym(s): IPH 4102; Anti-KIR3DL2/CD158k Reference Antibody (lacutamab)
- CAS No.: 2187368-16-5
- Formula:N/A
- Molecular Weight:(144.52 kDa)
IUPAC Name: (2Z,4E)-5-((1R,5R,8S)-8-hydroxy-1-methyl-5-(methyl-d3)-3-oxo-6-oxabicyclo[3.2.1]octan-8-yl-2,2,4-d3)-3-methylpenta-2,4-dienoic acid
SMILES: [Lacutamab]
Biological Activity: Lacutamab (IPH 4102) is a humanized monoclonal antibody targeting KIR3DL2/CD158k, which eliminates KIR3DL2-expressing cells via antibody-dependent cellular cytotoxicity and phagocytosis. Lacutamab is applicable to research related to mycosis fungoides, relapsed or refractory peripheral T-cell lymphoma, and relapsed or refractory cutaneous T-cell lymphoma[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lacutamab | ≥99.0% | Lacutamab (IPH 4102) is a humanized monoclonal antibody targeting KIR3DL2/CD158k, which eliminates KIR3DL2-expressing cells via antibody-dependent cellular cytotoxicity and phagocytosis. Lacutamab is applicable to research related to mycosis fungoides, relapsed or refractory peripheral T-cell lymphoma, and relapsed or refractory cutaneous T-cell lymphoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Bagot, M., et al. (2024). Lacutamab in patients with relapsed and/or refractory mycosis fungoides: results from the TELLOMAK phase 2 trial. Journal of Clinical Oncology, 42(16), 7082-7082.
-
[2]. Iyer, S. P., et al. (2023). Strategies to develop anti-KIR Mab lacutamab in patients with peripheral T-cell lymphoma: preliminary monotherapy clinical data and pre-clinical combinability data. Blood, 142, 3072.
